The Cooper Companies, Inc. (NYSE:COO) Momentum Shifts, Opening Near-Term Upside

CooperCompanies presents a short-term technical setup that favors upside pressure while fundamentals show mixed growth but free-cash strength supporting a valuation gap. The current picture points toward a tactical rebound opportunity against longer-term valuation headwinds.

Recent News

On July 24, 2025 the company announced the release date for its third-quarter 2025 financial results and scheduled a post-release call. On August 27, 2025 CooperCompanies released third-quarter fiscal 2025 results and updated fiscal guidance while noting continued operational priorities and share repurchases. On August 28, 2025 Citi Research downgraded the stock from Buy to Neutral and lowered its price target following the quarter’s execution commentary.

Technical Analysis

ADX registers 17.55, below the 20 threshold, indicating no established trend; that absence of trend frames price action as range-prone rather than strongly directional, reducing conviction for breakout bets while allowing mean-reversion moves to dominate near-term trading.

Directional indicators show DI+ at 20.9 with a dip-and-reversal, a bullish signal, while DI- sits at 22.48 and trends decreasing, which also supports short-term bullish bias. Together these readings favor a move higher if momentum sustains, particularly because the strength metric above does not yet confirm a strong trend.

MACD holds at -0.13 and the MACD line trades above the signal line (-0.55); the cross above the signal line produced a bullish signal and the MACD trend reads as increasing, signaling improving momentum even though MACD remains slightly negative.

MRO stands at -22.47 and shows a peak-and-reversal trend; the negative MRO indicates the price sits below the model target and therefore carries upside potential toward the implied target, with the magnitude signifying meaningful mean-reversion pressure if momentum supports it.

RSI at 48.33 and increasing places momentum in neutral territory with an upward tilt; that profile favors a stalled-to-modest advance rather than an overbought push, aligning with other indicators that suggest measured upside rather than an aggressive rally.

Price structure shows the close at $69.02 trading below the 200-day average of $79.17, which signals longer-term underperformance, while short-term averages behave differently: the 12-day EMA and 26-day EMA (both near $68.65–$68.66) trend upward and the 20-day average at $68.33 sits just below the price, reflecting short-term support. Ichimoku components place near-term resistance in the low $72 area (Senkou span values), and the super trend lower at $66.01 provides a nearby technical support reference. Bollinger band spacing remains narrow, implying contained volatility and reinforcing a range-bound regime with a bullish tilt if momentum persists.

 


Fundamental Analysis

Revenue and margin dynamics mixed: total revenue stands at $1,060,300,000 with revenue growth showing a QoQ increase of 48.46% but a YoY change of -9.39%. YoY revenue contraction contrasts with the sequential recovery signal, pointing to an uneven top-line recovery across reporting periods.

Margins: EBIT margin equals 16.72% and declined QoQ by -0.65% and YoY by -12.75%. The EBIT margin beats the industry peer mean of 10.417% yet falls just below the industry peer median of 17.23%, indicating operating profitability sits above typical peer average but slightly under the peer median. Operating margin at 16.57% tracks the same pattern and contracted YoY by -13.54%.

Earnings and cash flow: GAAP and adjusted metrics show EPS actual at $1.10 versus an estimate of $1.07, producing an EPS surprise of 2.80% and an EPS difference of $0.03. Forward EPS equals $1.02 while forward PE sits at 73.55. Free cash flow reached $164,500,000 with a free-cash-flow yield of 1.13%, above the industry peer mean of 0.50%, supporting a valuation argument driven by cash generation even as earnings multiples appear elevated.

Valuation and capital structure: P/B equals 1.74, below the industry peer mean of 2.40338 and below the peer median of 2.40516, while the trailing PE of 67.14 falls slightly below the industry peer mean of 71.52. Enterprise multiple sits at 61.95. Net debt totals $2,350,600,000 with debt-to-assets at 20.02% and debt-to-equity at 0.2967; interest coverage approximates 6.98x, providing reasonable near-term coverage for interest obligations.

Efficiency and working capital: cash-conversion-cycle days measure 245.73, well above the industry peer mean of 161.42, indicating a stretched working-capital position that heightens sensitivity to inventory and receivable turns. Asset-turnover ratio at 0.08554 sits slightly below the industry peer mean of 0.0941, signaling lower capital efficiency relative to peer average.

Profitability trends: return on equity equals 1.177% with QoQ improvement but a YoY decline of -10.901%; return on assets at 0.793% shows similar directionality. Earnings growth stands positive at 14.58% with YoY earnings growth at 12.69%, which supports the case for improving profitability despite margin compression versus the prior year.

Valuation summary: The current valuation as determined by WMDST rates the stock under-valued. That view rests on a combination of above-peer free-cash-flow yield, P/B below peer mean, and modestly lower trailing PE than the industry peer mean, offset by softer YoY revenue and margin contraction plus an extended cash conversion cycle. These factors create a valuation gap that WMDST interprets as under-valued given prevailing operational and cash-generation metrics.

MOST-RECENT QUARTERLY REPORT
REPORT PERIOD ENDING: 2025-07-31
REPORT DATE: 2025-08-27
NEXT REPORT DATE: 2025-11-25
CASH FLOW  Begin Period Cash Flow 116.2 M
 Operating Cash Flow 261.4 M
 Capital Expenditures -96.90 M
 Change In Working Capital -18.50 M
 Dividends Paid
 Cash Flow Delta 8.7 M
 End Period Cash Flow 124.9 M
 
INCOME STATEMENT REVENUE
 Total Revenue 1.1 B
 Forward Revenue 546.8 M
COSTS
 Cost Of Revenue 368.3 M
 Depreciation 45.4 M
 Depreciation and Amortization 95.4 M
 Research and Development 44.6 M
 Total Operating Expenses 884.6 M
PROFITABILITY
 Gross Profit 692.0 M
 EBITDA 272.7 M
 EBIT 177.3 M
 Operating Income 175.7 M
 Interest Income
 Interest Expense 25.4 M
 Net Interest Income -25.40 M
 Income Before Tax 151.9 M
 Tax Provision 53.6 M
 Tax Rate 35.3 %
 Net Income 98.3 M
 Net Income From Continuing Operations 98.3 M
EARNINGS
 EPS Estimate 1.07
 EPS Actual 1.10
 EPS Difference 0.03
 EPS Surprise 2.804 %
 Forward EPS 1.02
 
BALANCE SHEET ASSETS
 Total Assets 12.4 B
 Intangible Assets 5.5 B
 Net Tangible Assets 2.9 B
 Total Current Assets 2.1 B
 Cash and Short-Term Investments 124.9 M
 Cash 124.9 M
 Net Receivables 792.3 M
 Inventory 881.0 M
 Long-Term Investments 653.3 M
LIABILITIES
 Accounts Payable 255.9 M
 Short-Term Debt 46.0 M
 Total Current Liabilities 1.0 B
 Net Debt 2.4 B
 Total Debt 2.5 B
 Total Liabilities 4.0 B
EQUITY
 Total Equity 8.4 B
 Retained Earnings 7.6 B
VALUATION & PER-SHARE METRICS EQUITY & PER-SHARE METRICS
 Book Value Per-Share 42.01
 Shares Outstanding 198.813 M
 Revenue Per-Share 5.33
VALUATION
 Market Capitalization 14.5 B
 Enterprise Value 16.9 B
 Enterprise Multiple 61.946
Enterprise Multiple QoQ -14.757 %
Enterprise Multiple YoY -5.017 %
Enterprise Multiple IPRWA COO: 61.946
high: 60.952
median: 60.952
mean: 60.793
low: -62.011
 EV/R 15.932
CAPITAL STRUCTURE
 Asset To Equity 1.482
 Asset To Liability 3.076
 Debt To Capital 0.229
 Debt To Assets 0.2
Debt To Assets QoQ -3.856 %
Debt To Assets YoY 5986.322 %
Debt To Assets IPRWA high: 0.314
median: 0.314
mean: 0.314
COO: 0.2
low: 0.188
 Debt To Equity 0.297
Debt To Equity QoQ -4.889 %
Debt To Equity YoY 5810.359 %
Debt To Equity IPRWA high: 0.62
median: 0.597
mean: 0.597
COO: 0.297
low: 0.289
PRICE-BASED VALUATION
 Price To Book (P/B) 1.741
Price To Book QoQ -12.67 %
Price To Book YoY -25.066 %
Price To Book IPRWA high: 2.529
median: 2.405
mean: 2.403
COO: 1.741
low: 0.984
 Price To Earnings (P/E) 67.141
Price To Earnings QoQ -22.166 %
Price To Earnings YoY -30.289 %
Price To Earnings IPRWA high: 351.269
mean: 71.522
median: 70.629
COO: 67.141
low: -38.748
 PE/G Ratio 4.604
 Price To Sales (P/S) 13.712
Price To Sales QoQ -16.801 %
Price To Sales YoY -25.304 %
Price To Sales IPRWA high: 4179.118
COO: 13.712
mean: 13.702
median: 13.429
low: 2.761
FORWARD MULTIPLES
Forward P/E 73.554
Forward PE/G 5.044
Forward P/S 26.588
EFFICIENCY OPERATIONAL
 Operating Leverage 0.881
ASSET & SALES
 Asset Turnover Ratio 0.086
Asset Turnover Ratio QoQ 5.125 %
Asset Turnover Ratio YoY 3.023 %
Asset Turnover Ratio IPRWA high: 0.236
mean: 0.094
median: 0.094
COO: 0.086
low: 0.0
 Receivables Turnover 1.348
Receivables Turnover Ratio QoQ 0.683 %
Receivables Turnover Ratio YoY -4.045 %
Receivables Turnover Ratio IPRWA high: 2.865
mean: 1.445
COO: 1.348
low: 1.343
median: 1.343
 Inventory Turnover 0.418
Inventory Turnover Ratio QoQ 11.487 %
Inventory Turnover Ratio YoY -4.328 %
Inventory Turnover Ratio IPRWA high: 0.528
median: 0.528
mean: 0.528
COO: 0.418
low: 0.001
 Days Sales Outstanding (DSO) 67.695
CASH CYCLE
 Cash Conversion Cycle Days (CCC) 245.734
Cash Conversion Cycle Days QoQ -5.331 %
Cash Conversion Cycle Days YoY 8.532 %
Cash Conversion Cycle Days IPRWA high: 16936.777
COO: 245.734
mean: 161.424
low: 160.142
median: 160.142
CAPITAL DEPLOYMENT
 Cash Conversion Ratio 0.94
 CapEx To Revenue -0.091
 CapEx To Depreciation -2.134
 
CAPITAL, LIQUIDITY & COVERAGE CAPITAL STRUCTURE
 Total Capital 10.8 B
 Net Invested Capital 10.8 B
 Invested Capital 10.8 B
 Net Tangible Assets 2.9 B
 Net Working Capital 1.1 B
LIQUIDITY
 Cash Ratio 0.124
 Current Ratio 2.116
Current Ratio QoQ 0.808 %
Current Ratio YoY 6.497 %
Current Ratio IPRWA high: 3.656
COO: 2.116
mean: 2.016
median: 2.014
low: 1.465
 Quick Ratio 1.244
Quick Ratio QoQ 1.155 %
Quick Ratio YoY 5.131 %
Quick Ratio IPRWA high: 1.504
median: 1.504
mean: 1.504
low: 1.25
COO: 1.244
COVERAGE & LEVERAGE
 Debt To EBITDA 9.088
 Cost Of Debt 0.649 %
 Interest Coverage Ratio 6.98
Interest Coverage Ratio QoQ 0.133 %
Interest Coverage Ratio YoY 3.506 %
Interest Coverage Ratio IPRWA high: 8.398
median: 8.398
mean: 8.375
COO: 6.98
low: -10.187
 Operating Cash Flow Ratio 0.191
TIMING / LIQUIDITY
 Days Payables Outstanding (DPO) 70.597
DIVIDENDS
 Dividend Coverage Ratio
 Dividend Payout Ratio
 Dividend Rate
 Dividend Yield
PERFORMANCE GROWTH
 Asset Growth Rate -0.297 %
 Revenue Growth 5.787 %
Revenue Growth QoQ 48.461 %
Revenue Growth YoY -9.394 %
Revenue Growth IPRWA high: 12.301 %
COO: 5.787 %
mean: -3.892 %
median: -3.909 %
low: -56.322 %
 Earnings Growth 14.583 %
Earnings Growth QoQ 235.396 %
Earnings Growth YoY 12.688 %
Earnings Growth IPRWA high: 53.659 %
median: 53.659 %
mean: 50.26 %
COO: 14.583 %
low: -350.0 %
MARGINS
 Gross Margin 65.265 %
Gross Margin QoQ -3.674 %
Gross Margin YoY -1.286 %
Gross Margin IPRWA COO: 65.265 %
high: 65.015 %
median: 65.015 %
mean: 64.978 %
low: 35.847 %
 EBIT Margin 16.722 %
EBIT Margin QoQ -0.648 %
EBIT Margin YoY -12.752 %
EBIT Margin IPRWA high: 17.23 %
median: 17.23 %
COO: 16.722 %
mean: 10.417 %
low: -98489.789 %
 Return On Sales (ROS) 16.571 %
Return On Sales QoQ -1.545 %
Return On Sales YoY -13.54 %
Return On Sales IPRWA high: 17.673 %
median: 17.673 %
COO: 16.571 %
mean: 10.858 %
low: -98637.842 %
CASH FLOW
 Free Cash Flow (FCF) 164.5 M
 Free Cash Flow Yield 1.131 %
Free Cash Flow Yield QoQ 928.182 %
Free Cash Flow Yield YoY 75.621 %
Free Cash Flow Yield IPRWA COO: 1.131 %
high: 0.507 %
median: 0.507 %
mean: 0.5 %
low: -24.611 %
 Free Cash Growth 808.84 %
Free Cash Growth QoQ -1085.009 %
Free Cash Growth YoY 265.763 %
Free Cash Growth IPRWA COO: 808.84 %
high: 22.255 %
mean: -71.684 %
low: -71.774 %
median: -71.774 %
 Free Cash To Net Income 1.673
 Cash Flow Margin 18.231 %
 Cash Flow To Earnings 1.966
VALUE & RETURNS
 Economic Value Added 0.04
 Return On Assets (ROA) 0.793 %
Return On Assets QoQ 11.376 %
Return On Assets YoY -8.535 %
Return On Assets IPRWA high: 1.139 %
median: 1.139 %
mean: 1.135 %
COO: 0.793 %
low: -38.555 %
 Return On Capital Employed (ROCE) 1.56 %
 Return On Equity (ROE) 0.012
Return On Equity QoQ 11.248 %
Return On Equity YoY -10.901 %
Return On Equity IPRWA high: 0.022
median: 0.022
mean: 0.022
COO: 0.012
low: -0.654
 DuPont ROE 1.181 %
 Return On Invested Capital (ROIC) 1.059 %
Return On Invested Capital QoQ -74.774 %
Return On Invested Capital YoY -100.603 %
Return On Invested Capital IPRWA high: 2.262 %
mean: 1.57 %
median: 1.555 %
COO: 1.059 %
low: -11.418 %

Six-Week Outlook

Expect range-bound price action with a short-term upside bias. Technical signals — DI+ dip-and-reversal together with the MACD crossing above its signal line and an improving RSI — support a moderate rally toward the low-$72 zone defined by Ichimoku components and short-term moving averages. Key reference levels: near-term support clusters around the super trend lower at $66.01 and recent short-term averages in the $68 area; upside congestion appears near $72. A sustained move above the $72 region would require ADX confirmation to signal a durable trend; absent that confirmation, price likely remains prone to mean-reversion within the $66–$72 band.

About The Cooper Companies, Inc.

The Cooper Companies, Inc. (NYSE:COO) designs and manufactures medical devices, focusing on vision care and women’s health. Headquartered in San Ramon, California, the company structures its operations into two primary segments: CooperVision and CooperSurgical. CooperVision develops a wide array of contact lens products tailored to various vision correction requirements. Its product line includes spherical lenses for nearsightedness and farsightedness, as well as toric and multifocal lenses addressing astigmatism, presbyopia, and myopia. The company serves markets across the Americas, Europe, the Middle East, Africa, and the Asia Pacific, delivering high-quality eye care solutions globally. CooperSurgical enhances family and women’s healthcare by supplying a range of fertility products, medical devices, and contraceptive solutions. This segment supports healthcare professionals with innovative products like endometrial imaging devices, contraceptive IUDs, and fertility services, including genetic testing and cryostorage for cord blood and tissue. The Cooper Companies commits to quality and innovation, establishing itself as a dependable partner for healthcare professionals, distributors, and patients worldwide. The company aims to improve lives through superior vision care and women’s health solutions.



© 2025 WMDST — The World’s Most Dangerous Swing Trader. All rights reserved.